<DOC>
	<DOC>NCT00959686</DOC>
	<brief_summary>A Phase II clinical study to determine the efficacy of single agent Bendamustine for T cell lymphoma "BENTLY".</brief_summary>
	<brief_title>Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma</brief_title>
	<detailed_description>The primary objective of this study is to define the activity of Bendamustine for the treatment of T cells lymphomas. The activity of Bendamustine is determined by the response rate (RR) to the treatment within 22 days after intravenous infusion which enables to get a confidence interval of 95 % for the probability of an overall response rate (ORR).</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients aged more than 18 years. Refractory or relapsed peripheral Tcell NHL (PTCL) Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy ECOG score less than 2 No major organ dysfunction unrelated to lymphoma. Pregnant or breast feeding women ECOG score &gt; 2 Estimate survival time &lt; 3 months Active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy Creatinine clearance &lt; 10 ml/min or severe hepatic dysfunction not related to lymphoma. Previous chemotherapy/immunotherapy within 3 weeks before study entry Known seropositive for or active viral infection HIV, EBV, HCV CNS lymphoma Tcell Leukemia lymphoma associated with HTLV1 Sezary syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Bendamustine refractory or relapsed T-cell lymphoma.</keyword>
</DOC>